COVID-19 patients treated with the probiotic SLAB51-Sivomixx®800 have a significantly reduced risk of intubation and mortality. SLAB51 facilitates the proper oxygenation of critical organs by modulating oxygen consumption at the intestinal level, opening a new therapeutic scenario for hypoxia-related diseases such as chronic fatigue, neurodegenerative disorders, neonatal hypoxia and myocardial ischaemia. Studies have also proven the effectiveness of SLAB51 in Alzheimer, Parkinson and epilepsy.
